CNSY Stock Catalyst: Plus Therapeutics Begins Treating Patients in ReSPECT-LM Dose Optimization Trial for REYOBIQ

Jul 7, 2025 · 7:59pm ET

The trial focuses on Leptomeningeal Metastases.

Max move

+60.4%

High of day $12.05

Sparker timei

7:59pm ET

CNSY · Jul 7, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Plus Therapeutics, Inc. announced on July 08, 2025, that it has started treating initial patients in the ReSPECT-LM Dose Optimization Trial for its drug REYOBIQ, which targets Leptomeningeal Metastases.

The trial aims to optimize the dose of REYOBIQ for this specific condition. No specific amounts or filings were disclosed in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CNSY sparks.

Download Sniper App →

Catch the next CNSY-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →